

92/OCT/SE/2017/GBSL

October 25, 2017

To
The Manager
On-line Surveillance
BSE Limited
P J Towers, Dalal Street,
Mumbai -400001, India

BSE Scrip Code: 509079

Dear Sirs,

Sub: Reply to your letter on increase in volume

Ref: Your letter No. L/SURV/ONL/PV/NK/20172018/135 dated 25.10.2017


With reference to your letter dated October 25, 2017, we wish to inform you that the Company has made all the necessary disclosures pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 and has not withheld any material information/event that in our opinion would have a bearing on the price/volume behavior in the scrip.

Therefore, the increase in the share price/volume of the Company is purely due to market conditions and absolutely market driven and the management of the Company is in no way connected with any such increase in price/volume.

You are requested to take the same on records.

Thanking You,

For Gufic Biosciences Limited



Ami Shah
Company Secretary & Compliance Officer
Membership No. A39579

